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Abstract
Background: High-dose erythropoiesis-stimulating agents (ESA) for anemia of chronic kidney disease (CKD) have
been associated with adverse clinical outcomes and do not always improve erythropoiesis. We hypothesized that
high-dose ESA requirement would be associated with elevated inflammatory biomarkers, decreased adipokines,
and increased circulating, endogenous soluble erythropoietin receptors (sEpoR).
Methods: A cross-sectional cohort of anemic 32 CKD participants receiving ESA were enrolled at a single center
and cytokine profiles, adipokines, and sEpoR were compared between participants stratified by ESA dose
requirement (usual-dose darbepoetin-a (< 1 μg/kg/week) and high-dose (≥1 μg/kg/week)).
Results: Baseline characteristics were similar between groups; however, hemoglobin was lower among participants
on high-dose (1.4 μg/kg/week) vs usual-dose (0.5 μg/kg/week) ESA.
In adjusted analyses, high-dose ESA was associated with an increased odds for elevations in c-reactive protein and
interleukin-6 (p < 0.05 for both). There was no correlation between high-dose ESA and adipokines. Higher ESA
dose correlated with higher levels of sEpoR (rs = 0.39, p = 0.03). In adjusted analyses, higher ESA dose (per μcg/kg/
week) was associated with a 53% greater odds of sEpoR being above the median (p < 0.05).
Conclusion: High-dose ESA requirement among anemic CKD participants was associated with elevated
inflammatory biomarkers and higher levels of circulating sEpoR, an inhibitor of erythropoiesis. Further research
confirming these findings is warranted.
Trial registration: Clinicaltrials.gov NCT00526747
Background
Clinical trials in patients with chronic kidney disease
(CKD) have demonstrated that attempting to achieve a
higher hemoglobin with erythropoiesis-stimulating
agents (ESA) leads to adverse cardiovascular outcomes
[1-4]. Recently, secondary analyses have suggested the
increased cardiovascular morbidity and mortality among
anemic CKD participants randomized to higher hemo-
globin targets may be partially explained by the use of
high-doses of ESA [5,6]. While it has been suggested
that ESA therapy may be proinflammatory [7] or have
direct toxic effects on the cardiovascular system [8,9],
the underlying mechanism of the elevated cardiovascular
risk associated with high-dose ESA has yet to be
elucidated.
Inflammation and malnutrition among patients with
CKD have been demonstrated to be significant contribu-
tors to accelerated atherosclerosis and increased cardio-
vascular mortality [10-13], and may contribute to the
excess risk associated with high-dose ESA. Although ele-
vations of select inflammatory cytokines have been
demonstrated in anemic CKD patients treated with ESA
and in CKD patients overtly resistant to ESA therapy
[14,15], a clear dose relationship has not been demon-
strated. Further, chronic inflammation can lead to pro-
tein energy wasting which may mediate another
pathway for adverse cardiovascular outcomes in CKD
patients [16,17]. As a result, persistent elevations in
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may also be associated with adipokine dysregulation.
In addition to a potential association with inflamma-
tion and malnutrition, increasing ESA requirement and
dosing does not always result in improved hemoglobin
levels, the reasons for which are unclear. Erythropoietin
stimulates erythropoiesis by binding to its cell surface
receptor EpoR - a member of the cytokine receptor
family that is expressed on erythroid cells in the bone
marrow. An alternatively spliced mRNA isoform of
EpoR giving rise to a soluble form (sEpoR) that lacks
the transmembrane domain of the receptor and poten-
tially secreted into extracellular space has been
described [18-21]. A recombinant form of human sEpoR
has been shown to bind Epo with high affinity and act
as a potent Epo antagonist in diverse in vitro and in
vivo experimental models [22-25]. Endogenous sEpoR
has been detected in human serum and plasma [26-29]
but its physiologic role and biologic activity have not
been defined. Whether endogenous sEpoR may modu-
late the erythropoietic response to ESA therapy is not
known and the relationship between circulating sEpoR
levels and ESA dosing in anemic patients with CKD
remains to be characterized.
We hypothesized that the requirement for high-dose
ESA therapy in some anemic CKD patients may be asso-
ciated with elevated inflammatory markers and/or
impaired nutritional status. Finding such an association
may provide an insight into possible mechanisms for the
adverse outcomes associated with high-dose ESA admin-
istration. Secondly, we hypothesized that there may be a
direct relationship between increasing ESA dose require-
ment and higher levels of circulating sEpoR. To address
these questions, this study compared demographic fac-
tors, C-reactive protein (CRP), cytokine profiles, adipo-
nectin, leptin, and plasma soluble erythropoietin
receptor levels in a cross-sectional cohort of anemic
CKD participants who required treatment with either
high-doses or usual-doses of ESA.
Methods
Patients
The study sample is a prospective cohort of anemic
CKD patients treated with ESA therapy enrolled from
the Durham Nephrology anemia clinic, a private practice
in Durham, North Carolina. Inclusion criteria included:
≥ 18 years of age, CKD defined as an estimated glomer-
ular filtration rate < 60 ml/min/1.73 m
2 using the Modi-
fication of Diet in Renal Disease Study II equation
(eGFR (ml/min per 1.73 m
2) = 186 × [Cr (mg/100 ml)]
-
1.154 x (age)
-0.203 x (1.21 if subject is black)), active treat-
ment with darbepoetin-a therapy, and anemia deemed
secondary to chronic kidney disease. Exclusion criteria
included: an active gastrointestinal (GI) bleed or history
of GI bleed within the prior 3 months, uncontrolled
hyperparathyroidism (parathyroid hormone > 550),
untreated vitamin B12 or folate deficiency, untreated
iron deficiency (transferrin saturation < 20% and ferritin
< 100), overt infection, active hemolysis, hemoglobino-
pathies, known adverse response to ESA, prior kidney
transplant or aluminum toxicity.
Patients were screened for enrollment and all patients
requiring high-dose ESA therapy over the prior 3
months (defined a priori as receiving ≥ 1 mcg/kg/week
of darbepoetin-a) and a random sample of patients
requiring usual-dose ESA therapy (defined ap r i o r ias <
1 mcg/kg/week darbepoetin-a) were screened and
enrolled between September 1, 2007 and April 31, 2008.
Patients were identified by record review. On the day of
the patient’s appointment in the anemia management
clinic, patients were approached by study personnel to
ask if they were interested in participating in the study.
If the patients agreed to participate, they were asked to
sign informed consent and a HIPAA form. Following
informed consent, the following data were collected
(through a one-on one participant interview and chart
review): age, weight, ESA doses during the previous 3
months, dosing interval, blood pressure, heart rate, past
medical history, and medications. Laboratory measures
including serum albumin, hemoglobin, iron status,
serum chemistry, and parathyroid hormone (analyzed at
one central laboratory) were collected as part of routine
patient care and were retrieved through chart review.
After the interview, the participant was scheduled for a
5 ml blood draw prior to the administration of the next
ESA dose at the subsequent anemia clinic visit. All
blood samples were immediately processed and stored
at -80°C until analysis.
The study was approved by the Duke University Medi-
cal Center Institutional Review Board and was registered
with clinicaltrials.gov (NCT00526747).
Biochemical analyses
Utilizing multiplex protein array technology (Thermo
Fisher Scientific, Massachusetts, USA), the plasma was
assayed for the following cytokines: interferon-g, TNF-a,
IL-1b, IL-2, IL-6, IL-8, IL-10, IL-12p40 and IL-12p70
[30]. Details are available in Additional File 1. All mea-
surements were run in duplicate and the laboratory
technicians were blinded to the clinical characteristics of
the subjects being studied.
C-reactive protein was determined by a commercially
available highly sensitive latex-based immunoassay and
quantitatively measured using an immunoturbidimetric
assay on the Hitachi autoanalyzer (Roche Diagnostics,
Indianapolis, USA).
Adiponectin and circulating leptin concentrations
were analyzed by radioimmunoassay (Linco Research,
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described and validated [31]. The assays employ a poly-
clonal (rabbit) antibody raised against recombinant
human adiponectin and leptin, respectively. The gamma
counter used for these measurements was a Perkin-
Elmer Wallac Wizard 1470.
For quantification of sEpoR in plasma, samples were
analyzed via ELISA (R&D Systems, Minneapolis, MN).
Details are available in Additional File 2.
Statistical analysis
Continuous data are presented as means (standard
deviations) or medians (25-75% interquartile range) and
compared with the Satterthwaite two sample t-test or
Wilcoxon rank sum test. Categorical data are presented
as counts and percents and compared with the chi
2 sta-
tistic or Fisher’s exact test.
Given the non-normal distribution of cytokines and
adipokines, markers were divided into quartiles and
logistic regression was performed to calculate an odds
ratio (case-control relative risk) for having a biomar-
ker above/below the median among participants on
high-dose ESA vs normal-dose ESA, as previously
described [7]. In adjusted analyses of predictors of
inflammatory cytokines, models were controlled for
gender, hemoglobin, and ferritin. A graphical bar plot
was created for the odds (5-95% CI) of cytokines
being above the median among participants on high
vs usual dose ESA. In adjusted analyses of predictors
of adipokines, models were adjusted for gender, hemo-
globin and weight.
Analyses of sEpoR were performed similarly. To gra-
phically describe the relationship between ESA dose and
sEpoR, a scatter plot with a linear regression line (95%
confidence intervals of the predicted mean) was gener-
ated. In adjusted analyses of predictors of sEpoR, the
model was adjusted for gender, hemoglobin, eGFR, and
ESA dose.
All data was analyzed using SAS Eguide 4.1 (SAS
Institute, North Carolina, USA).
Results
Participant Characteristics by ESA Dose
A total of 11 participants requiring high-dose ESA ther-
apy (≥ 1 mcg/kg/wk of darbepoetin-a) and 21 partici-
pants treated with usual-dose ESA therapy (< 1 mcg/kg/
wk of darbepoetin-a) were enrolled into the study.
Demographics, baseline characteristics, and medications
were similar between groups (Table 1). While most
laboratory parameters were similar between groups, the
3-month average hemoglobin was 10.4 g/dl in the high-
dose ESA group compared to 11.5 g/dl in the usual-
dose ESA (p = 0.0005).
ESA dose and inflammatory biomarkers
The median levels (pg/ml) of inflammatory biomarkers
among participants on high-dose and usual-dose ESA
are shown in Table 2. The unadjusted odds ratio for
participants on high-dose ESA and having an inflamma-
tory biomarker above the median were compared with
participants on usual-dose ESA and having an inflam-
matory biomarker above the median (Table 2). In all,
participants on high-dose ESA (vs usual-dose ESA) were
more likely to exhibit inflammatory biomarkers above
the median, but only CRP was statistically significant.
After adjusting for gender, hemoglobin, and ferritin,
high-dose ESA therapy was independently associated
with an increased odds ratio of CRP and of IL-6 being
above the median (Table 2, Figure 1). While not statisti-
cally significant, all other inflammatory cytokines tested
(including IFN-g,T N F - a,I L - 1 b,I L - 2 ,I L - 8 ,I L - 1 0 ,I L -
12p40, and IL-12p70) were more likely to be above the
median among participants on high-dose ESA compared
to usual-dose ESA.
ESA dose and adipokines
The median level of adiponectin (ng/ml) was 18, 718.6
among participants on usual-dose ESA and 15, 397.4
among participants on high-dose ESA (Table 3). Given
the inverse relationship between adiponectin and clinical
outcomes [32], we tested whether participants on high-
dose ESA were more likely to have an adiponectin level
below the median. In unadjusted analyses, there was no
difference between groups in odds of adiponectin being
below the medians; however, in adjusted analyses there
were trends towards lower odds of adiponectin being
below the median among those on high-dose vs usual
dose ESA (Table 3).
The median level of leptin (ng/ml) was 30.9 and 43.4
among participants on high-dose and usual-dose ESA,
respectively (Table 3). Neither unadjusted nor adjusted
analyses identified significant differences in odds of lep-
tin levels being below the median between groups.
ESA dose and Soluble Epo Receptor
The median level of soluble Epo receptor (sEpoR) was
2.5 pg/ml among participants on high-dose ESA and 0.7
pg/ml among participants on usual-dose ESA. In unad-
justed analyses, 63.6% of participants on high-dose ESA
were above the median of sEpoR compared to 42.9% of
participants on usual-dose ESA.
By the Spearman’sr a n kc o r r e l a t i o nt e s t ,t h e r ew a sa
modest correlation between 3-month average ESA dose
(in mcg/kg/week) and sEpoR (rs = 0.39, p = 0.03). The
relationship between ESA dose and sEpoR can be seen
graphically in Figure 2. Considering this relationship
may have been partially explained by differences in
Inrig et al. BMC Nephrology 2011, 12:67
http://www.biomedcentral.com/1471-2369/12/67
Page 3 of 10Table 1 Demographics and baseline characteristics of the cohort of anemic chronic kidney disease participants treated
with usual or high-dose ESA
Variable High-dose ESA
(≥1 mcg/kg/wk of
darbepoetin-a)
(n = 11)
Usual-dose ESA
(< 1 mcg/kg/wk of
darbepoetin-a)
(n = 21)
P-value
Age 71.1 ± 11.2 67.4 ± 10.2 0.38
Primary Cause of Kidney Disease (%) 0.13
Diabetes 3 (27.3%) 10 (47.6%)
Hypertension 3 (27.3%) 6 (28.6%)
Glomerulonephritis 0 (0.0%) 2 (9.5%)
Unknown 3 (27.3%) 0 (0.0%)
Other 2 (18.2%) 3 (14.3%)
Male Sex 1 (9%) 8 (38.1%) 0.11
Race (%) 0.71
Black 5 (45.5%) 12 (57.1%)
White 6 (54.6%) 9 (42.9%)
Weight (kg) 80.6 ± 29.6 92.0 ± 21.8 0.28
Blood Pressure (mmHg)
Systolic 127.0 ± 11.0 130.0 ± 16.2 0.54
Diastolic 67.2 ± 8.3 68.8 ± 13.1 0.72
Heart rate (beats/min) 80.4 ± 19.4 74.3 ± 11.2 0.36
Baseline Comorbidities (%)
Diabetes, non insulin requiring 3 (27.3%) 7 (33.3%) 0.99
Diabetes, insulin requiring 5 (45.5%) 9 (42.9%) 0.99
Cerebrovascular accident 0 (0.0%) 3 (14.3%) 0.53
Hypertension 11 (100.0%) 21 (100.0%) 0.99
Hyperparathyroidism 7 (63.6%) 15 (71.4%) 0.70
Congestive heart failure 2 (18.2%) 1 (4.8%) 0.27
Cancer 0 (0.0%) 2 (9.5%) 0.53
Coronary artery disease 3 (27.3%) 6 (28.6%) 0.99
Darbepoetin-a dose (3-month average) 94.1 mcg/week (1.4 mcg/kg/week) 49.7 mcg/week
(0.5 mcg/kg/week)
0.001
Baseline Medications (%)
Vitamin D 7 (63.6%) 14 (66.7%) 0.99
HMG-CoA reductase inhibitor 7 (63.6%) 10 (47.6%) 0.47
Oral Iron 7 (63.6%) 17 (81.0%) 0.40
Intravenous Iron 1 (9.1%) 1 (4.8%) 0.99
Non-calcium containing phosphorus
binder
0 (0.0%) 1 (4.8%) 0.99
Calcium-containing phosphorus
binder
2 (18.2%) 3 (14.3%) 0.99
Coumadin 2 (18.2%) 1 (4.8%) 0.27
Aspirin 6 (54.6%) 14 (66.7%) 0.70
ACE/ARB 7 (63.6%) 16 (76.2%) 0.68
Alpha antagonist 0 (0.0%) 4 (19.1%) 0.27
Beta blocker 6 (54.6%) 13 (61.9%) 0.72
Calcium channel blocker 5 (45.5%) 10 (47.6%) 0.99
Nitroglycerin 1 (9.1%) 3 (14.3%) 0.99
Hematology Laboratory Values
3-month average hemoglobin (g/dl) 10.4 ± 0.7 11.5 ± 0.8 0.0005
Hemoglobin at enrollment (g/dl) 10.8 ± 1.0 12.3 ± 0.9 0.0004
Serum Iron (mcg/dl) 75.9 ± 31.6 78.1 ± 21.8 0.94
Serum Ferritin (ng/ml, median, IQR) 343.0 (224.0, 673.0) 353.0 (314.0, 493.0) 0.93*
Inrig et al. BMC Nephrology 2011, 12:67
http://www.biomedcentral.com/1471-2369/12/67
Page 4 of 10hemoglobin, we tested whether there was a correlation
between hemoglobin and sEpoR, however no significant
relationship was identified (rs = -0.20, p = 0.3). There
was also no correlation between any of the aforemen-
tioned cytokines and sEpoR (data not shown). We also
performed logistic regression to determine if average
ESA dose (in mcg/kg/week) remained independently
associated with a sEpoR level above the median. In
adjusted analyses, higher ESA dose (per mcg/kg/week
increase) was significantly associated with a greater odds
of sEpoR being above the median (OR 1.53, CI 1.03-2.3,
p = 0.04).
Discussion
Anemia of chronic kidney disease is common, yet the
optimal treatment to improve outcomes remains uncer-
tain. In light of recent analyses demonstrating high-dose
ESA therapy to be associated with adverse outcomes
[4-6], our study sought to describe biochemical altera-
tions which may be associated with high-dose ESA.
Among participants treated with higher doses of ESA,
we identified significantly higher levels of inflammatory
markers CRP and IL-6, which could be in the causal
pathway for adverse outcomes associated with high-dose
ESA. Second, our study is the first to describe in vivo a
Table 1 Demographics and baseline characteristics of the cohort of anemic chronic kidney disease participants treated
with usual or high-dose ESA (Continued)
Transferrin saturation, % 28.9 ± 10.3 32.1 ± 8.6 0.59
Chemistry Laboratory Values
Serum blood urea nitrogen (mg/dl) 58.3 ± 24.8 54.6 ± 14.8 0.66
Serum creatinine (mg/dl) 2.6 ± 1.2 2.7 ± 1.1 0.88
MDRD GFR (ml/min per 1.73 m
2) 25.9 ± 15.1 25.9 ± 9.3 0.99
Serum glucose (mg/dl, median, IQR) 109.0 (88.0, 134.0) 113.0 (89.0, 154.5) 0.47*
Serum albumin (mg/dl) 4.0 ± 0.4 3.9 ± 0.3 0.38
Serum phosphorus (mg/dl) 4.5 ± 1.0 4.1 ± 0.6 0.22
Serum PTH (pg ml
-1, median, IQR) 148.5 (39.0, 208.0) 99.0 (52.0, 167.0) 0.59*
*nonparametric test used
Table 2 Median cytokine levels among participants treated with high-dose and usual-dose ESA and unadjusted and
adjusted odds of cytokine being above the median
Variable High-dose ESA
(≥1 mcg/kg/wk of
darbepoetin-a)
(n = 11)
Usual-Dose ESA
(< 1 mcg/kg/wk of
darbepoetin-a)
(n = 21)
Unadjusted Odds Ratio, *
(5-95% CI)
p-value
Adjusted Odds Ratio**,
(5-95% CI)
p-value
C-reactive protein (mg/l) 7.7 (4.8, 9.7) 2.4 (1.1, 9.2) 9.0 (1.5-53.4)
p = 0.01
16.0 (1.5-174.5)
p = 0.02
Interferon-g (pg/mL) 12.4 (4.4, 18.3) 8.5 (3.8, 11.2) 4.3 (0.88-21.3)
p = 0.06
4.5 (0.5-37.2)
p = 0.2
Tumor necrosis factor-a (pg/mL) 68.7 (10.3, 202.4) 41.2 (15.8, 65.6) 1.32 (0.31-5.7)
p = 0.7
1.7 (0.2-14.4)
p = 0.6
Interleukin-1b (pg/mL) 1.0 (0.2, 2.0) 0.6 (0.3, 1.6) 1.32 (0.31-5.7)
p = 0.7
1.3 (0.1-11.4)
p = 0.8
Interleukin-2 (pg/mL) 18.2 (6.3, 33.1) 9.2 (4.5, 22.2) 4.3 (0.88-21.3)
p = 0.06
2.4 (0.3-18.8)
p = 0.4
Interleukin-6 (pg/mL) 21.3 (17.3, 26.3) 16.2 (13.5, 21.9) 4.3 (0.88-21.3)
p = 0.06
12.3 (1.1-143.2)
p = 0.04
Interleukin-8 (pg/mL) 63.5 (33.9, 63.5) 44.5 (34.3, 65.0) 1.32 (0.31-5.7)
p = 0.7
1.1 (0.2-8.3), p = 0.9
Interleukin-10 (pg/mL) 4.2 (1.3, 7.6) 1.5 (1.0, 3.3) 4.3 (0.88-21.3)
p = 0.06
4.3 (0.5-35.0)
p = 0.2
IL-12p40 (pg/mL) 32.8 (15.9, 37.0) 22.8 (16.1, 32.2) 2.3 (0.52-10.5)
p = 0.45
3.1 (0.4-23.2) p = 0.3
IL-12p70 (pg/mL) 4.4 (1.1, 8.1) 2.7 (1.6, 4.0) 4.3 (0.88-21.3)
p = 0.06
5.6 (0.7-47.2)
p = 0.1
Median and 25
th to 75
th interquartile range
*Odds ratio of cytokine being above the median among those in high vs usual dose ESA,
**Adjusted for gender, hemoglobin and ferritin
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receptor in CKD patients as a potential modulator of
erythropoietic response to ESA therapy. However, given
the observational nature of our study, further studies are
required to confirm these findings.
ESA dose and inflammation
Although the association between chronic kidney disease
and elevated inflammatory biomarkers has been well
established, the relationship between CKD-related ane-
mia, inflammation/oxidative stress and the use of ESAs
Adjusted Odds Ratio
Favors elevated cytokine 
on normal-dose ESA 
Favors elevated cytokine 
on high-dose ESA 
Figure 1 Adjusted odds ratio for elevated inflammatory cytokines associated with high-dose vs usual-dose ESA therapy. Odds ratios
were adjusted for gender, hemoglobin, and ferritin.
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study by Keithi-Reddy et al demonstrated that CKD-
related anemia is not only associated with elevated
inflammatory cytokines but patients with CKD-related
anemia treated with ESA also have higher TNF-a and
IL-6 levels compared to ESA-naïve anemic CKD patients
[7]. Other studies in CKD patients have demonstrated
ESA resistance to be associated with elevated
inflammatory cytokines, including IL-6, IFN-g,a n d
TNF-a[34-37]. Our study extends these prior observa-
tions by demonstrating that patients who are adminis-
t e r e dh i g h e rE S Ad o s e s( e v e ni fn o to v e r t l yE S A
resistant) also exhibit higher levels of inflammatory bio-
markers, including IL-6 and CRP. Given our small sam-
ple size and the short duration of our study, further
prospective studies will need to define whether changes
Table 3 Median adipokine levels among participants treated with high-dose and usual-dose ESA and unadjusted and
adjusted odds of adipokine being below the median
Variable High-dose ESA
(≥1 mcg/kg/wk of
darbepoetin-a)
(n = 11)
Usual-Dose ESA
(< 1 mcg/kg/wk of
darbepoetin-a)
(n = 21)
Unadjusted Odds Ratio, *
(5-95% CI)
p-value
Adjusted Odds Ratio, * (5-95% CI)
p-value
Adiponectin (ng/ml) 18718.6 (13328.6, 33469.4) 15397.4 (8032.5, 53063.7) 0.76 (0.2-3.3)
p = 0.7
7.8 (0.5-109.2)
p = 0.1
Leptin (ng/ml) 30.9 (1.5, 102.6) 43.4 (9.8, 82.6) 2.33 (0.5-10.5)
p = 0.3
1.7 (0.1-19.2)
p = 0.7
*Odds of cytokine being below the median among those in high vs usual dose ESA,
**Adjusted for gender, hemoglobin, and weight
Figure 2 Relationship between soluble Epo Receptor level and ESA dose. Scatter plot with linear regression line (Y = b0+b1X) and 95%
confidence intervals of the mean predicted value of soluble Epo Receptor.
Inrig et al. BMC Nephrology 2011, 12:67
http://www.biomedcentral.com/1471-2369/12/67
Page 7 of 10in ESA dose effect the levels of inflammatory biomar-
kers over time.
ESA dose and adipokines
Adverse outcomes related to chronically elevated inflam-
matory biomarkers have in part been explained by the role
of cytokines in the development of the protein-energy
wasting [38-40]. In our study we compared plasma adipo-
nectin and leptin levels in participants treated with usual
and high-dose ESA. Despite differences in IL-6 and CRP
which have been associated with protein-energy wasting,
we found no significant relationship between high-dose
ESA dose and low levels of adiponectin or leptin. Our fail-
ure to find a difference between participants may be due
to a number of factors. First, development of nutritional
dysregulation related to inflammation likely occurs over
longer periods than observed in our short study. Second,
our cohort was a healthier group of CKD participants
separate and distinct from hemodialysis patients in which
protein energy wasting is more prevalent. Finally, our
small sample size, may have limited our discriminatory
capability to identify significant differences.
ESA dose and soluble EPO receptor
In this study, we postulated that circulating plasma sEpor
levels may be relatively elevated in CKD patients requir-
ing high doses of ESA for the treatment of anemia and
found that higher ESA dose requirement was correlated
with higher levels of circulating sEpoR. Unlike one prior
study [29], we found no relationship between other mea-
sured cytokines and plasma sEpoR level. We also found
no relationship between hemoglobin level and sEpoR
suggesting severity of anemia may not correlate with
sEpoR levels, consistent with the findings of previous stu-
dies [26,27,41]. Although a recombinant form of sEpoR
was shown to act as an antagonist of Epo in in vitro and
in vivo studies of Epo-EpoR biology and function, it is
not known whether low levels of endogenous, circulating
plasma sEpoR can directly modulate erythropoietic
responses to exogenous ESAs. While this study is the
first to assess the relationship between ESA dose and
sEpoR level among CKD patients, one previous study
which measured sEpoR levels in patients with liver and
kidney disease [28] reported elevated sEpoR levels in the
plasma of five hemodialysis patients on EPO when com-
pared to healthy controls. In the current study, we did
not measure pre-ESA plasma sEpoR levels and therefore
cannot determine whether ESA therapy itself may be
involved in upregulation of sEpoR level in a dose-depen-
dent manner. An alternative possibility is that higher
baseline sEpoR levels prior to ESA therapy initiation may
serve as a predictor of ESA response and dose require-
ment. In fact, a recent retrospective analysis among inci-
dent hemodialysis patients identified higher sEpoR levels
at dialysis initiation to be associated with higher ESA
requirements [29]. Further studies are needed to charac-
terize the relationship between endogenous sEpoR and
ESA responses and to elucidate the physiologic role of
sEpoR on regulation and control of erythropoiesis.
Limitations
Our study has several limitations. It was an observational
cohort and causality cannot be determined, thus our
results should be considered hypothesis generating. Sec-
ond, our study measured biomarkers and sEpoR levels at
one point in time in patients already on ESA therapy;
thus we cannot determine the relationship between
changes in ESA and changes in these parameters over the
course of therapy or prior to administration of ESA. Pro-
spective studies which measure biomarkers over time to
determine the natural course and changes in these bio-
markers in individual patients could help further eluci-
date whether our findings are due to patient-specific
factors or in fact related to ESA dose. Finally, our sample
size was modest and further studies with larger numbers
of patients should be performed to confirm our results.
Conclusions
In conclusion, our study demonstrates that patients
requiring high-dose ESA for treatment of CKD-related
anemia are more likely to have increased levels of the
pro-inflammatory biomarkers IL-6 and CRP. We also
observed an association between higher dose ESA ther-
apy and increased circulating endogenous sEpoR levels.
Longitudinal studies of changes in sEpoR levels and
cytokines with variations in ESA dosing and hemoglobin
levels are warranted to confirm these findings.
Additional material
Additional file 1: Measurement of cytokines. Detailed description of
the techniques used to measure the reported cytokines.
Additional file 2: Measurement of soluble Epo receptor. Detailed
description of the techniques used to measure soluble Epo receptor.
Acknowledgements
We are extremely grateful to Dr. Robert Gutman and his group as well as
their anemia clinic nurse manager Rae McCullough at Durham Nephrology
in allowing us to enroll patients from their anemia clinic for the study. In
addition, we would like to thank Dr. Mike Muehlbauer and Huaxia Cui for
their expertise in the cytokine analysis and development of the soluble
erythropoietin receptor assay for plasma. Dr. Inrig was supported by NIH
grant KL2 RR024127, NIH grant K23 HL092297 and by a grant from the Ralph
Snyderman Foundation. Dr. Patel was supported by NIH grant K23
DK075929.
Author details
1Department of Medicine, University of Texas Southwestern Medical Center,
5323 Harry Hines Blvd, Dallas, Texas, 75390-8523, USA.
2Department of
Medicine, Duke University Medical Center, 2301 Erwin Road, Durham, North
Inrig et al. BMC Nephrology 2011, 12:67
http://www.biomedcentral.com/1471-2369/12/67
Page 8 of 10Carolina, 27708, USA.
3Department of Medicine, Duke Clinical Research
Institute, 2400 Pratt Street, Durham, North Carolina, 27705, USA.
Authors’ contributions
JI and LS created and designed the study. SB contributed to the collection
and interpretation of the data. JI performed statistical analysis. UP
contributed to the design of the study and to the interpretation of the data.
MA contributed to the analysis and interpretation of the data. All authors
have been involved in drafting the manuscript or revising it critically for
important intellectual content and have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 June 2011 Accepted: 12 December 2011
Published: 12 December 2011
References
1. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D:
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl
J Med 2006, 355(20):2085-2098.
2. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D,
Burger HU, Scherhag A: Normalization of hemoglobin level in patients
with chronic kidney disease and anemia. N Engl J Med 2006,
355(20):2071-2084.
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM,
Schwab SJ, Goodkin DA: The effects of normal as compared with low
hematocrit values in patients with cardiac disease who are receiving
hemodialysis and epoetin. N Engl J Med 1998, 339(9):584-590.
4. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU,
Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, et al: A trial of
darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J
Med 2009, 361(21):2019-2032.
5. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD,
Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and
achieved hemoglobin outcomes. Kidney Int 2008, 74(6):791-798.
6. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin
requirements predict mortality in hemodialysis patients. Am J Kidney Dis
2004, 44(5):866-876.
7. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK:
Association of anemia and erythropoiesis stimulating agents with
inflammatory biomarkers in chronic kidney disease. Kidney Int 2008,
74(6):782-790.
8. Smith KJ, Bleyer AJ, Little WC, Sane DC: The cardiovascular effects of
erythropoietin. Cardiovasc Res 2003, 59(3):538-548.
9. Vaziri ND, Zhou XJ: Potential mechanisms of adverse outcomes in trials
of anemia correction with erythropoietin in chronic kidney disease.
Nephrol Dial Transplant 2009, 24(4):1082-1088.
10. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L,
Jogestrand T: Strong association between malnutrition, inflammation,
and atherosclerosis in chronic renal failure. Kidney Int 1999,
55(5):1899-1911.
11. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G: Biomarkers of
inflammation and progression of chronic kidney disease. Kidney Int 2005,
68(1):237-245.
12. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ,
Balakrishnan VS: Plasma interleukin-6 predicts cardiovascular mortality in
hemodialysis patients. Am J Kidney Dis 2005, 45(2):324-333.
13. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S,
Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in
hemodialysis patients. Kidney Int 1998, 54(1):236-244.
14. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK:
Association of anemia and erythropoiesis stimulating agents with
inflammatory biomarkers in chronic kidney disease. Kidney Int 2008.
15. Smrzova J, Balla J, Barany P: Inflammation and resistance to
erythropoiesis-stimulating agents–what do we know and what needs to
be clarified? Nephrol Dial Transplant 2005, 20(Suppl 8):viii2-7.
16. Stenvinkel P: Malnutrition and chronic inflammation as risk factors for
cardiovascular disease in chronic renal failure. Blood Purif 2001,
19(2):143-151.
17. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJG, Balakrishnan VS, the HEMO
Study Group: Plasma adiponectin levels and clinical outcomes among
haemodialysis patients. Nephrol Dial Transplant 2008, 23(8):2619-2628.
18. Todokoro K, Kuramochi S, Nagasawa T, Abe T, Ikawa Y: Isolation of a cDNA
encoding a potential soluble receptor for human erythropoietin. Gene
1991, 106(2):283-284.
19. Nagao M, Masuda S, Abe S, Ueda M, Sasaki R: Production and ligand-
binding characteristics of the soluble form of murine erythropoietin
receptor. Biochem Biophys Res Commun 1992, 188(2):888-897.
20. Kuramochi S, Ikawa Y, Todokoro K: Characterization of murine
erythropoietin receptor genes. J Mol Biol 1990, 216(3):567-575.
21. Fujita M, Takahashi R, Liang P, Saya H, Ashoori F, Tachi M, Kitazawa S,
Maeda S: Role of alternative splicing of the rat erythropoietin receptor
gene in normal and erythroleukemia cells. Leukemia 1997, 11(Suppl
3):444-445.
22. Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF,
Miyazono K, Urabe A, Takaku F: Establishment and characterization of a
unique human cell line that proliferates dependently on GM-CSF, IL-3,
or erythropoietin. J Cell Physiol 1989, 140(2):323-334.
23. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R:
In vivo evidence that erythropoietin protects neurons from ischemic
damage. Proc Natl Acad Sci USA 1998, 95(8):4635-4640.
24. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS,
Cerami A, Brines M, Rosenbaum DM: Erythropoietin administration
protects retinal neurons from acute ischemia-reperfusion injury. Proc
Natl Acad Sci USA 2002, 99(16):10659-10664.
25. Haroon ZA, Amin K, Jiang X, Arcasoy MO: A Novel Role for Erythropoietin
During Fibrin-Induced Wound-Healing Response. Am J Pathol 2003,
163(3):993-1000.
26. Harris KW, Winkelmann JC: Enzyme-linked immunosorbent assay detects
a potential soluble form of the erythropoietin receptor in human
plasma. Am J Hematol 1996, 52(1):8-13.
27. Baynes RD, Reddy GK, Shih YJ, Skikne BS, Cook JD: Serum form of the
erythropoietin receptor identified by a sequence-specific peptide
antibody. Blood 1993, 82(7):2088-2095.
28. Westphal G, Braun K, Debus J: Detection and quantification of the soluble
form of the human erythropoietin receptor (sEpoR) in the growth
medium of tumor cell lines and in the plasma of blood samples. Clin Exp
Med 2002, 2(1):45-52.
29. Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R:
Soluble erythropoietin receptor contributes to erythropoietin resistance
in end-stage renal disease. PLoS One 2010, 5(2):e9246.
30. Moody MD, Van Arsdell SW, Murphy KP, Orencole SF, Burns C: Array-based
ELISAs for high-throughput analysis of human cytokines. Biotechniques
2001, 31(1):186-190, 192-184.
31. Ma Z, Gingerich R, Santiago J, Klein S, Smith C, Landt M:
Radioimmunoassay of leptin in human plasma. Clin Chem 1996,
42(6):942-946.
32. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S,
Malatino LS, Bonanno G, Seminara G, Rapisarda F, et al: Adiponectin,
metabolic risk factors, and cardiovascular events among patients with
end-stage renal disease. J Am Soc Nephrol 2002, 13(1):134-141.
33. Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G: Association of
inflammation with anaemia in patients with chronic kidney disease not
requiring chronic dialysis. Nephrol Dial Transplant 2008, 23(9):2879-2883.
34. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong
predictor of resistance to erythropoietin in hemodialysis patients. Am J
Kidney Dis 1997, 29(4):565-568.
35. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD:
Effect of malnutrition-inflammation complex syndrome on EPO
hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney
Dis 2003, 42(4):761-773.
36. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC:
Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma,
TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor
response to erythropoietin therapy. J Am Soc Nephrol 2003,
14(7):1776-1784.
37. Macdougall IC, Cooper AC: Erythropoietin resistance: the role of
inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant
2002, 17(Suppl 11):39-43.
Inrig et al. BMC Nephrology 2011, 12:67
http://www.biomedcentral.com/1471-2369/12/67
Page 9 of 1038. Kalantar-Zadeh K, Kopple JD: Relative contributions of nutrition and
inflammation to clinical outcome in dialysis patients. Am J Kidney Dis
2001, 38(6):1343-1350.
39. Kaizu Y, Kimura M, Yoneyama T, Miyaji K, Hibi I, Kumagai H: Interleukin-6
may mediate malnutrition in chronic hemodialysis patients. Am J Kidney
Dis 1998, 31(1):93-100.
40. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L,
Franch H, Guarnieri G, Ikizler TA, Kaysen G, et al: A proposed nomenclature
and diagnostic criteria for protein-energy wasting in acute and chronic
kidney disease. Kidney Int 2008, 73(4):391-398.
41. Yoshida S, Bessho M, Sakate K, Hirasawa I, Murayoshi M, Hirashima K: Lack
of relationship between soluble erythropoietin receptor levels and
erythroid parameters in anemic patients. Blood 1996, 88(8):3246-3247.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2369/12/67/prepub
doi:10.1186/1471-2369-12-67
Cite this article as: Inrig et al.: Association between high-dose
erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble
erythropoietin receptors. BMC Nephrology 2011 12:67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Inrig et al. BMC Nephrology 2011, 12:67
http://www.biomedcentral.com/1471-2369/12/67
Page 10 of 10